|
|
Article: Biologics: overcapacity concern rears its head.(Cover Story)
- Article from:
- Chemical Week
- Article date:
- June 25, 2003
- Author:
CopyrightCOPYRIGHT 2003 Access Intelligence, LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Contract manufacturing firms have been investing heavily in biologic drug production in the past few years to offset the slump in demand for small-molecule pharma intermediates. Companies including Akzo Nobel, Avecia, Cambrex, Dow Chemical, Degussa, DSM, and Lonza have spent heavily building biologics capacity and acquiring biomanufacturing firms in anticipation of a wave of new drug approvals that experts forecast would require upwards of 1 million liters of new contract biologics capacity.
However, delays in the launch of some biologic drugs coupled with continued investment in new plants may be leading to short-term overcapacity in the biologics sector. Lonza ...